泰林生物(300813) - 2022 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2022 was ¥71,534,758.17, representing a 48.90% increase compared to ¥48,043,207.85 in the same period last year[3] - Net profit attributable to shareholders was ¥13,925,179.08, up 45.08% from ¥9,598,366.31 year-over-year[3] - The net profit after deducting non-recurring gains and losses was ¥13,681,580.11, reflecting a 50.32% increase from ¥9,101,615.73 in the previous year[3] - Basic earnings per share increased by 50.00% to ¥0.27 from ¥0.18 in the previous year[3] - The company reported an operating profit of ¥14,799,499.51, which is a 36.5% increase from ¥10,868,948.87 in the prior year[16] - The total profit for the first quarter was CNY 14,890,543.35, an increase from CNY 10,900,775.66 year-over-year[17] Cash Flow and Liquidity - The net cash flow from operating activities improved significantly to -¥2,502,547.74, a 78.80% improvement from -¥11,806,521.67 in the same quarter last year[3] - Operating cash inflow for the first quarter was CNY 88,001,208.41, up from CNY 63,240,845.86 year-over-year[18] - The company reported cash and cash equivalents at the end of the period amounting to CNY 319,191,845.37, compared to CNY 157,527,939.81 at the end of the previous year[20] - The company received CNY 205,800,000.00 from financing activities, indicating strong capital inflow[20] - The net cash flow from financing activities was CNY 204,469,339.64, a significant increase compared to CNY -594,000.00 in the previous year[20] Assets and Liabilities - Total assets at the end of the reporting period were ¥866,700,209.21, a 32.14% increase from ¥655,871,410.07 at the end of the previous year[3] - Current assets totaled ¥720,336,324.97, an increase of 39.9% from ¥514,456,491.95 at the start of the year[13] - The company's cash and cash equivalents rose to ¥517,191,845.37, compared to ¥302,461,349.97 at the beginning of the year, marking a 71.1% increase[12] - Total liabilities increased to ¥285,078,298.41, up from ¥158,490,874.47, indicating a growth of 79.8%[14] - The equity attributable to shareholders reached ¥581,621,910.80, a significant increase from ¥497,380,535.60 at the beginning of the year, reflecting a growth of 16.9%[14] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 6,180[7] - Shareholders' equity attributable to shareholders was ¥581,621,910.80, up 16.94% from ¥497,380,535.60 at the end of the previous year[3] Research and Development - Research and development expenses increased to ¥13,701,030.39, representing a 47.5% rise compared to ¥9,286,741.64 in the previous year[16] Government Support and Future Plans - The company received government subsidies amounting to ¥80,302.58 during the reporting period[5] - The company has plans for market expansion and new product development, although specific details were not disclosed in the report[15]